Fig. 3

Annexin A2 confers cisplatin resistance is associated with decreased apoptosis. a A549/DDP cells were transfected with Annexin A2 siRNA, and then treated with 5 μM cisplatin for 48 h, cells were stained with Annexin V-FITC and propidium iodide, and the cell apoptosis were analyzed by flow cytometry. b A549 cells were transfected with pCMV6-Annexin A2, and then treated with 5 μM cisplatin for 48 h, cells were stained with Annexin V-FITC and propidium iodide, the cell apoptosis were analyzed by flow cytometry. c A549/DDP cells were transfected with Annexin A2 siRNA, and then treated with 5 μM cisplatin for 24 h, Caspase 3/7 activity were measured. d A549 cells were transfected with pCMV6-Annexin A2, and then treated with 5 μM cisplatin for 24 h, Caspase 3/7 activity were measured. e A549/DDP cells were transfected with Annexin A2 siRNA, and then treated with 5 μM cisplatin for 48 h, the expression of PARP and cleaved PARP were measured by Western blot. f A549 cells were transfected with pCMV6-Annexin A2, and then treated with 5 μM cisplatin for 48 h, (upper) the expression of PARP and cleaved PARP were measured by Western blot, (lower) the relative density of Cleaved PARP. *P < 0.05